Business Intelligence Analyst

Globus Medical announces acquisition of Higgs Boson Health to transform healthcare experience through ai-driven digital solutions. August 26, 2026 17:57 ET | Source: Globus Medical AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) - Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. With a mission to transform healthcare experience through digital innovation, Higgs Boson will position Globus Medical to shape patient and provider experience throughout the full episode of care. "Higgs Boson employs highly experienced teams of software developers and AI scientists who will be joining our team to power our vision of a seamless digital healthcare environment to simplify a patient's journey through our healthcare system while enhancing real-time information and surgical intelligence available to healthcare providers with the ultimate goal of getting to 95% good outcomes at 10 years for all musculoskeletal surgeries," said David Paul, Founder and Executive Chairman. "The acquisition of Higgs Boson and its digital solutions represents the next step in our strategy of enhancing the Globus ecosystem," commented Keith Pfeil, President and Chief Executive Officer. "As we continue to build out the ecosystem, the Higgs Boson technology will be part of our surgical intelligence pillar, bringing together outcomes and analytics in a closed-loop manner that fosters continuous learning, integrating along the full patient journey with the goal of improving patient outcomes." About Globus Medical, Inc. Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com. Safe Harbor Statements All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan" and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC"), including the sections labeled "Risk Factors" and "Cautionary Note Concerning Forward-Looking Statements," and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the "Company", "Globus", "Globus Medical", "we", "us", and "our" refers to Globus Medical, Inc.

Globus Medical has acquired Higgs Boson Health, a Durham-based digital healthcare company incubated at Duke University. The deal brings AI-driven software designed to enhance patient and provider experience throughout the full episode of musculoskeletal care. Higgs Boson's team of software developers and AI scientists will join Globus Medical to support its vision of a seamless digital healthcare environment. The technology will be integrated into the company's surgical intelligence pillar, combining outcomes and analytics across the patient journey. Globus Medical aims to achieve 95% good outcomes at 10 years for all musculoskeletal surgeries through enhanced digital tools and real-time information for healthcare providers. The acquisition represents the company's continued strategy of building out its healthcare ecosystem. Financial terms of the transaction were not disclosed in the announcement.

Globus Medical's assessed fair value has been cut from $107.42 to $103.23, a 3.9% reduction reflecting more cautious growth expectations. Analysts remain divided on the medical device company's prospects. BMO Capital and Wells Fargo highlight strong earnings power, with NuVasive synergies ahead of schedule and Nevro turning accretive faster than expected. Wells Fargo noted Q2 earnings per share of $1.34 exceeded expectations, with management raising 2026 EPS guidance to $4.95–$5.05. However, Stifel slashed its price target from $95 to $80, citing weaker Nevro and Enabling Technologies performance. UBS initiated coverage at Neutral with an $82 target, describing spine market procedure growth as low single digit. The fair value reduction reflects revenue growth trimmed from 6.30% to 5.83%, though profit margins improved from 18.40% to 20.58%.